MetaCap

Boundless Bio (BOLD) vs Xilio Therapeutics (XLO)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Boundless Bio (BOLD) has outperformed Xilio Therapeutics (XLO) over the past year, gaining 105.3% versus a loss of 28.3%. Boundless Bio is the larger company by market cap ($54.8 million vs $53.4 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

BOLD+105.31%XLO-28.29%
+175%+67%-42%
Nov 21, 20251 yearNov 20, 2026
BOLD-83.72%XLO-50.00%
+28%-35%-99%
Mar 25, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

BOLD versus XLO key metrics
MetricBOLDXLO
Share price$2.32$7.56
Market cap$54.78M$53.40M
1-day change-2.52%-1.11%
YTD return+93.33%-15.63%
1-year return+105.31%-28.29%
5-year return—-97.29%
P/E ratio (TTM)—11.63
EPS (TTM)$-2.46$0.65
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$43.77M
Revenue growth (YoY)—+589.88%
Net income (latest FY)$-58.20M$-35.04M
Operating margin—-95.92%
Net margin—-80.05%
52-week high$3.16$10.71
52-week low$0.961$6.47
Distance from 52-week high-26.68%-29.41%
Analyst consensusnonenone
Avg. price target upside+72.41%+164.55%
Average volume131.34K11.54K
Shares outstanding23.61M7.06M
Employees2876
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • BOLD has outperformed XLO by 133.6 percentage points over the past year.

About Boundless Bio

BOLD stock →

Boundless Bio, Inc., a clinical-stage oncology company, develops interrogating extrachromosomal DNA (ecDNA) directed therapies for treating patients with oncogene amplified cancers. Its lead product candidate is BBI-940, an ecDNA-directed therapeutic candidate (ecDTx) that is in Phase 1/2 clinical trial in patients with estrogen receptor positive and human epidermal growth factor receptor 2 negative breast cancer, as well as patients with triple-negative breast cancer luminal androgen receptor subtype.

Health Care · Biotechnology: Pharmaceutical Preparations · 28 employees

About Xilio Therapeutics

XLO stock →

Xilio Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery and development of masked immuno-oncology therapies. The company's pipeline includes XTX501, a bispecific PD-1 / masked IL-2, for patients with metastatic non-small cell lung cancer; Efarindodekin alfa, an investigational, masked IL-12, that is in Phase 2 clinical trial for patients with advanced solid tumors; and Vilastobart, an investigational tumor-activated, Fc-enhanced, high affinity binding anti-CTLA-4 monoclonal antibody.

Health Care · Biotechnology: Pharmaceutical Preparations · 76 employees

BOLD vs XLO FAQ

Which is bigger, Boundless Bio or Xilio Therapeutics?

Boundless Bio (BOLD) is larger, with a market capitalization of $54.78M compared with $53.40M for Xilio Therapeutics (XLO).

Which stock has performed better over the past year, BOLD or XLO?

BOLD returned +105.31% over the past 12 months, compared with -28.29% for XLO (price return, excluding dividends). Past performance does not predict future results.

Are Boundless Bio and Xilio Therapeutics in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons